ABUS
Arbutus BiopharmaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive readouts/cost reductions or a value-accretive partnership/financing at favorable terms could re-rate shares toward higher analyst highs and specialist takeover/partner interest, supporting the bull target.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +0.2.
What can break
Clinical/program delays or negative data
Momentum
54
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.68 · Bull $7.35 · Bear $3.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $7.00
Why
Momentum54 · Δ7d +11.7
Value41 · Δ7d +0.1
Sentiment77 · Δ7d +0.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
54
34% active weight
Current posture
7d trendImproving
Δ7d
+11.7
Δ21d
+29.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
77
33% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+6.6
Why this grade
Composite grade B. Momentum 54.3 / Value 41.1 / Sentiment 76.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$884.97M
Beta
0.72
Shares Out
192.32M
P/E (TTM) · Derived
-12.1
P/S (TTM)
62.02
P/FCF (TTM) · Derived
-19.39
Rev YoY
-60.5%
EPS YoY
+61.3%
Gross Margin
-
Op Margin
-320.4%
Net Debt
-$122.62M
Current Ratio
18.80
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology